Thrice weekly iron supplementation non-inferior to thrice-daily treatment for iron-deficiency anemia
1. This noninferiority trial found that at 12 weeks, hematologic responses to 200 mg ferrous fumarate thrice weekly (TIW) were ...
Tag: hematology
Characterizing idiopathic CD4 lymphocytopenia 30-years after its initial description
1. In this observational study, idiopathic CD4 lymphocytopenia (ICL) was associated with an increased risk of opportunistic infections, malignancy, and ...
POT1-mediated long telomere syndrome is associated with familial clonal hematopoiesis
1. In this retrospective study, carriers with mutations in the gene encoding the protection of telomeres 1 protein (POT1) were ...
Characterization of cancer development risk following pediatric radiation exposure from computed tomography
Evidence rating level: 3 (Average) 1. Exposure to a higher cumulative number of pediatric CT scans is associated with a ...
2 Minute Medicine Rewind May 29, 2023
Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial 1. Rivaroxaban is ...
Quizartinib improves overall median survival in patients with acute myeloid leukemia
1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion ...
Once-a-month fitusiran reduces bleeding rates in patients with hemophilia A and B with inhibitors
1. Annualized bleeding rate was reduced by 91% in the fitusiran prophylaxis group compared to the bypassing agents on-demand group. ...
Dersimelagon reduces symptomatic disease in erythropoietic protoporphyrias
1. In this randomized controlled trial, oral dersimelagon resulted in significantly increased time to first symptoms among patients with erythropoietic ...
Donor sex has no effect on survival in patients receiving red blood cell transfusions
1. In this randomized controlled trial, donor sex did not result in a significant difference in mortality amongst patients receiving ...
#VisualAbstract: Carfilzomib, dexamethasone, and lenalidomide superior to lenalidomide monotherapy for multiple myeloma
Click to read this study in The Lancet Oncology.
